Orchid Pharma announced Q2FY23 results: Revenue jumps 36% QoQ and 36% YoY EBITDA jumps 154% QoQ and 133% YoY Manish Dhanuka, Managing Director, Orchid Pharma, said, “Our revenues have seen a sharp uptick over the past year. We have focussed on increasing capacity utilisations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results are a sign of positive things to come." Result PDF
Conference Call with Orchid Pharma Management and Analysts on new business updates. Listen to the full transcript.